Skip to search formSkip to main contentSkip to account menu

laropiprant

Known as: (-)-((3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic Acid 
A prostaglandin D2 receptor (DP1) antagonist with niacin-induced vasodilation inhibiting activity. Laropiprant binds to and inhibits the activity of… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

MK-0524

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport
Objectives— Postprandial atherogenic lipoproteins, characterizing high-risk patients, correlate positively with cardiovascular… 
2015
2015
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
2015
2015
Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients
Background The aim of this study was to explore the influence of extended-release niacin/laropiprant (ERN/LRP) versus placebo on… 
2014
2014
Coronary artery disease: HDL and coronary heart disease—novel insights
The association between HDL cholesterol and cardiovascular events, and the potential antiatherogenic effects of HDL particles… 
2014
2014
Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia
Introduction Nicotinic acid (NA) has been associated with reduced cardiovascular morbidity and mortality. Of note, beyond its… 
Review
2012
Review
2012
Safety and tolerability of extended-release niacin with laropiprant
Introduction: Niacin is one of the oldest drugs used in the treatment of dyslipidemia. Previously its use has been limited… 
2010
2010
Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects
Laropiprant (LRPT) has been shown to reduce flushing symptoms induced by niacin and has been combined with niacin for treatment… 
Review
2010
Review
2010
A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin
Importance of the field: Despite effective lowering of low-density lipoprotein cholesterol (LDL-C) with statin for prevention of… 
Review
2009
Review
2009
Extended-Release Niacin (Nicotinic Acid)/Laropiprant
Abstract▴ Extended-release (ER) niacin (nicotinic acid)/ laropiprant is a once-daily fixed-dose combination tablet that has been… 
2009
2009
Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
Laropiprant (LRPT), a prostaglandin D(2) receptor-1 antagonist shown to reduce niacin-induced flushing symptoms, has been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)